Item 7.01. Regulation FD Disclosure.
On January 24, 2020, Predictive Oncology Inc. (the "Company" announced that it
has signed a letter of intent to acquire Quantitative Medicine (QM).
QM is a biomedical analytics and computational biology company, founded by Dr.
Robert Murphy and Dr. Joshua Kangas, both of Carnegie Mellon University, that
has developed a novel, computational drug discovery platform called CoRE. CoRE
is designed to dramatically reduce the time, cost and financial risk of
discovering new therapeutic drugs by predicting the main effects of drugs on
target molecules that mediate disease. Predictive Oncology's Helomics division
has built an AI knowledgebase of drug response profiles from over 150,000 cancer
cases. Upon completion of a transaction with QM, the Company would be able to
use AI to integrate information with CoRE to build robust predictive models of
how specific types of tumors will react to cancer drug therapies.
Completion of the transaction, which is expected to be completed in the first
two quarters of 2020, is subject to the negotiation of a definitive agreement
and other terms and conditions. Terms were not disclosed, but the transaction is
expected to be an all-stock transaction.
The Company's press release is furnished as Exhibit 99.1 and is incorporated
herein by reference.
Item 9.01. Financial Statements and Exhibits.
(a) Not applicable.
(b) Not applicable.
(c) Not applicable.
(d) Exhibits.
Exhibit No. Description
99.1 Press release dated January 24, 2020
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses